Tags

Type your tag names separated by a space and hit enter

Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
Photodermatol. 1985 Aug; 2(4):252-6.P

Abstract

A bioavailability study was performed with a pill containing microcrystalline 8-MOP and a soft gelatine capsule containing dissolved 8-MOP in 35 patients receiving PUVA treatment. Peak plasma levels were almost doubled after ingestion of the capsule preparation in comparison with those recorded from the pill takers. The pharmaceutical formulation of 8-MOP preparations is of decisive importance for the bioavailability of the drug. Variations in degree of absorption from different 8-MOP preparations and the existence of a metabolic first-pass effect probably explain the great inter-patient variability in therapeutic response. It is therefore advisable to individualize the dose of 8-MOP, primarily in slow responders, with the aim of obtaining a faster clearance but also to reduce the amount of UVA light involved.

Authors

Nørgaard M
No affiliation info available
Hueg B
No affiliation info available
Staberg B
No affiliation info available

MeSH

Biological AvailabilityCapsulesClinical Trials as TopicCrystallizationHumansMethoxsalenPUVA TherapyPsoriasisSolutions

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

3903679

Citation

Nørgaard, M, et al. "Bioavailability Study of Two Different 8-methoxypsoralen (8-MOP) Preparations in Patients Receiving PUVA Therapy." Photo-dermatology, vol. 2, no. 4, 1985, pp. 252-6.
Nørgaard M, Hueg B, Staberg B. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy. Photodermatol. 1985;2(4):252-6.
Nørgaard, M., Hueg, B., & Staberg, B. (1985). Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy. Photo-dermatology, 2(4), 252-6.
Nørgaard M, Hueg B, Staberg B. Bioavailability Study of Two Different 8-methoxypsoralen (8-MOP) Preparations in Patients Receiving PUVA Therapy. Photodermatol. 1985;2(4):252-6. PubMed PMID: 3903679.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy. AU - Nørgaard,M, AU - Hueg,B, AU - Staberg,B, PY - 1985/8/1/pubmed PY - 1985/8/1/medline PY - 1985/8/1/entrez SP - 252 EP - 6 JF - Photo-dermatology JO - Photodermatol VL - 2 IS - 4 N2 - A bioavailability study was performed with a pill containing microcrystalline 8-MOP and a soft gelatine capsule containing dissolved 8-MOP in 35 patients receiving PUVA treatment. Peak plasma levels were almost doubled after ingestion of the capsule preparation in comparison with those recorded from the pill takers. The pharmaceutical formulation of 8-MOP preparations is of decisive importance for the bioavailability of the drug. Variations in degree of absorption from different 8-MOP preparations and the existence of a metabolic first-pass effect probably explain the great inter-patient variability in therapeutic response. It is therefore advisable to individualize the dose of 8-MOP, primarily in slow responders, with the aim of obtaining a faster clearance but also to reduce the amount of UVA light involved. SN - 0108-9684 UR - https://www.unboundmedicine.com/medline/citation/3903679/Bioavailability_study_of_two_different_8_methoxypsoralen__8_MOP__preparations_in_patients_receiving_PUVA_therapy_ DB - PRIME DP - Unbound Medicine ER -